The FDA cleared Access MeMed BV, a host-response blood test that helps distinguish bacterial from viral infections in adults and children in as little as 15 minutes.
News|Articles|October 17, 2022
The Daily Dose: Adult RSV Vaccine
Author(s)Sydney Jennings
Advertisement
Patient Care brings primary care clinicians a lot of medical news every day—it’s easy to miss an important study.
The Daily Dose provides a concise summary of one of the website's leading stories you may not have seen.
On October 14, 2022, we reviewed a pivotal phase 3 clinical trial of an investigational respiratory syncytial virus (RSV) vaccine (RSVPreF3 OA) for older adults.
The study
The phase 3 randomized placebo-controlled AReSVi-006 trial enrolled 25 000 participants from 17 countries to evaluate efficacy of a single dose of the adjuvanted RSVPreF3 OA investigational vaccine in adults aged ≥60 years. Findings, which will be presented at IDWeek 2002 later this month, showed overall vaccine efficacy of 82.6% against RSV-lower respiratory tract disease, satisfying the trial’s primary endpoint.
A note from the manufacturer
“These are truly exceptional results given that today RSV remains one of the major infectious diseases without a vaccine, despite over 60 years of research,” said GSK chief scientific officer Tony Wood in a statement.
The company believes that these robust findings suggest the potential for RSVPreF3 OA to help reduce the global burden of RSV-LRTD, and particularly among older and the most vulnerable adults.
Click here for the full study review.
Advertisement
Related to this article
Catch up on the 9 FDA drug approvals most relevant to primary care, including new options for HIV-1 infection, narcolepsy, diabetes, pain management, and more.
Evolocumab was associated with a 20% lower risk of fatal or nonfatal myocardial infarction than ezetimibe among more than 544 000 adults with ASCVD.
Greater Mediterranean diet adherence was associated with lower odds of adult acne, particularly among women, in a UK Biobank study of dietary patterns.
Abbott's investigational device achieved 96.3% complete left atrial appendage closure by echocardiography, with a 1.8% ischemic stroke rate at 1 year.
October FDA news included updates on long-acting olanzapine, multi-cancer blood testing, stroke rehabilitation, and heart failure monitoring.
Christoph Correll, MD, discusses the new once-monthly olanzapine injection for schizophrenia, including clinical efficacy, metabolic risks, and patient selection.
Cheryl Cox Kinney, MD, explains when night sweats warrant further evaluation, including red flags, persistent symptoms, and potential nonmenopausal causes.
Advertisement
Advertisement